<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563563</url>
  </required_header>
  <id_info>
    <org_study_id>NB-401</org_study_id>
    <nct_id>NCT00563563</nct_id>
  </id_info>
  <brief_title>A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent</brief_title>
  <official_title>An Open-Label Study Assessing the Safety and Efficacy of Naltrexone Sustained Release (SR) in Combination With Bupropion Sustained Release (SR) in Overweight and Obese, Nicotine-Dependent Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexigen Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orexigen Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a combination of naltrexone SR and
      bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and
      obese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess rates of smoking cessation defined by continuous abstinence.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the percent change from baseline in total body weight during the entire study</measure>
    <time_frame>Baseline to endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the rates of smoking cessation as measured by expired CO levels &lt;10 ppm</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the change from baseline in tobacco use from baseline as measured by a tobacco use diary</measure>
    <time_frame>Baseline to endpoint</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Nicotine Dependence</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>NB32</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone SR 32 mg/Bupropion SR 360 mg daily subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NB32</intervention_name>
    <description>All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.</description>
    <arm_group_label>NB32</arm_group_label>
    <other_name>Contrave</other_name>
    <other_name>Naltrexone SR 32 mg/Bupropion SR 360 mg daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Ancillary therapy</intervention_name>
    <description>During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.</description>
    <arm_group_label>NB32</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Female and male subjects must be 18 to 65 years of age;

          2. Have body mass index (BMI) greater than or equal to 27 and less than or equal to
             45kg/m2;

          3. Have smoked an average of at least 10 cigarettes/day in the preceding year, with &lt; 3
             month total abstinence period;

          4. Self-reported level of motivation to stop smoking â‰¥ 7, on a scale of 1-to-10;

          5. At least moderately concerned about gaining weight after quitting smoking

          6. Women of child-bearing potential, must be non-lactating and agree to use effective
             contraception throughout the study period and 30 days after discontinuation of study
             drug;

          7. Able to comply with all required study procedures and schedule;

          8. Able to speak and read English;

          9. Willing and able to give written informed consent.

        Key Exclusion Criteria:

          1. Obesity of known endocrine origin

          2. Serious medical condition

          3. History of drug or alcohol abuse or dependence

          4. Use of excluded concomitant medications

          5. History of surgical or device (e.g. gastric banding) intervention for obesity;

          6. History or predisposition to seizures

          7. Pregnant or breast-feeding women or planning to become pregnant during the study
             period or within 30 days of discontinuing study drug;

          8. Planned surgical procedure that can impact the conduct of the study;

          9. Use of investigational drug, device or procedure within 30 days prior to Screening;

         10. Participation in any previous clinical trial conducted by Orexigen Therapeutics;

         11. Any condition which in the opinion of the investigator makes the subject unsuitable
             for inclusion in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nader Oskooilar, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmacology Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <disposition_first_submitted>October 25, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 25, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 31, 2012</disposition_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotine-dependence in overweight and obese subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

